免疫神経薬の開発動向

当レポートでは、世界の免疫神経薬市場における新製品の治験・開発動向について分析し、免疫神経製品の定義・分類方法や共通標的、現在の治験の進行状況 - 疾患別・フェーズ別・地域別など -、最大手企業10社の概略と主力製品、今後の技術・市場動向に対する専門家の見解、といった情報を取りまとめてお届けいたします。

第1章 イントロダクション

第2章 エグゼクティブ・サマリー

第3章 神経免疫製品の定義と分類

第4章 神経免疫学の共通目標：概要

• サイトカイン
• リンパ球／分子と、活性化・融合作用との関連性
• その他の共通標的：神経免疫製品の場合

第5章 上市済み神経免疫製品の評価

• 症状・分子の種類
• 標的の種類

第6章 パイプライン上の神経免疫製品の評価

• 製品一覧：治験フェーズ (開発段階) 別
• 製品一覧：分子の種類別
• 製品一覧：標的別

第7章 特定症状の分析：多発性硬化症 (MS)

• 疾患の概要と疫学
• 製品開発活動
• 治験の最終段階にある製品のプロファイル

第8章 特定症状の分析：アルツハイマー病 (AD)

• 疾患の概要と疫学
• 製品開発活動
• 治験の最終段階にある製品のプロファイル

第9章 免疫神経薬の治験の動向

• 現在進行中の治験：活動拠点別の傾向
• 現在進行中の治験：相 (フェーズ) 別・後援企業別の傾向
• 現在進行中の治験：分析対象の症状別の傾向
• 併用療法の傾向
• 神経免疫市場内部のアンメットニーズ

第10章 付録

Among the different molecule types in neuroimmunology, mAbs and small molecules are the most common. This is primarily due to the specificity of the former and the ability of the latter to penetrate the BBB. However, the cost factor associated with mAbs-based therapy is seen as a hurdle for wider market acceptances.

Neuroimmunology is expected to be an area that will witness strong growth in the future due to a number of factors such as deeper understanding of the underlying disease pathology, advancements in neurogenetics, and potential of these drugs that can contribute to targeted therapy. Pipeline drugs targeting a number of neurology indications are being developed; however, the most common ones are Alzheimer's disease (AD) and Multiple Sclerosis (MS).

The most common targets adopted by pipeline drugs for MS include cytokines or cytokine receptors, as well as lymphocytes or molecule s associated with their activation or migration. The majority of pipeline drugs for AD are aimed at targeting the AB protein, the historical results of which have not been strong enough to be assigned as a breakthrough therapy.

The KOLs interviewed have highlighted the high cost of therapy associated with a mAb based therapy which is perceived as a hurdle for such drugs to be widely accepted in the market; this factor is expected to lead companies to develop more cost-efficient therapies based on alternate molecule types. They've also expressed the need for long-term safety and clinical data, as well as data to help them with decisions on sequential or combination therapies in neuroimmunology. These challenges are compounded when rare diseases are considered, primarily those related to patient recruitment.

The "Neuroimmunology Drug Development", report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape. This report provides an overview of current clinical and product development trends for neuroimmunology within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including analysis of the most common targets and molecule types that are being evaluated among the current pipeline drugs, focus on product development in indications such as AD and MS, and unmet needs within neuroimmunology.

Scope:

This report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape. Components of the slide deck include primary and secondary research -

• Quotes from 10 key opinion leaders (3 US, 5 EU, 1 Japan, 1 China)

• Summary of neuroimmunology product definitions and classifications

• Overview of common targets and molecule types among current pipeline drugs, with focus on product development in AD and MS

• Trends in ongoing clinical trials in neuroimmunology based on sponsor type, and phase of development

• Call-outs of key information and details

• Insight from GlobalData's specialist neurology analysts.

Reasons to buy:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the neuroimmunology market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the neuroimmunology market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Introduction

• 1.1. Related Reports
• 1.2. Upcoming Related Reports

2. Executive Summary

• 2.1. Key Findings
• 2.2. KOL Insights on Neuroimmunology Competitive Landscape

3. Neuroimmunology Product Definition and Classification

• 3.1. GlobalData's Definition of Neuroimmunology Products

4. Overview of Common Targets in Neuroimmunology

• 4.1. Cytokines
• 4.2. Lymphocytes or Molecules Associated with their Activation or Migration
• 4.3. Other Common Targets in Neuroimmunology

5. Assessment of Marketed Neuroimmunology Products

• 5.1. Indications and Molecule Types
• 5.2. Target Types

6. Assessment of Pipeline Neuroimmunology Products

• 6.1. Products in Different Phases of Development
• 6.2. Products by Different Molecule Types
• 6.3. Products by Different Targets

7. Indication Specific Overview: Multiple Sclerosis

• 7.1. Disease Overview and Epidemiology
• 7.2. Product Development Activity
• 7.3. Profiles of Products in Late - Stage Development

8. Indication Specific Overview: Alzheimer's Disease

• 8.1. Disease Overview and Epidemiology
• 8.2. Product Development Activity
• 8.3. Profiles of Products in Late - Stage Development

9. Trends in Clinical Trials of Neuroimmunology Drugs

• 9.1. Geographical Locations of Ongoing Clinical Trials
• 9.2. Ongoing Clinical Trials by Different Phases and Sponsor Type
• 9.3. Indications Being Evaluated in Ongoing Clinical Trials
• 9.4. Combination Therapy Trends in Ongoing Clinical Trials
• 9.5. Unmet Needs Within Neuroimmunology

10. Appendix

• 10.1. Sources
• 10.2. Primary Research
• 10.3. About the Authors
• 10.4. About GlobalData
• 10.5. Contact Us
• 10.6. Disclaimer